目的 探讨参麦注射液对结直肠癌化疗患者免疫功能的影响。方法 选取2017-03至2018-02青海省人民医院收治的结直肠癌化疗患者88例,随机分为研究组和对照组,每组44例。全部患者采用XELOX化疗方案治疗,对照组采用脾多肽治疗,研究组在对照组基础上,采用参麦注射液治疗,根据RECIST实体瘤疗效标准评估两组的疗效。检测两组治疗前后的血清CD3+、CD4+、CD4+/CD8+、NK细胞。采用卡氏评分(KPS)评估两组的生存质量,记录两组的不良反应发生情况。结果 两组的缓解率对比,研究组为43.18%,对照组为36.36%,差异无统计学意义(P>0.05)。两组的有效率对比,研究组(84.09%)高于对照组(65.09%),差异有统计学意义(P<0.05)。研究组治疗后的CD3+、CD4+、CD4+/CD8+、NK细胞明显升高,且高于对照组治疗后的水平,差异有统计学意义(P<0.05)。研究组的生存质量改善程度(36.36%)优于对照组(27.27%),差异有统计学意义(P<0.05)。研究组的恶心呕吐、白细胞减少、肝损伤、神经毒性发生率均低于对照组,差异有统计学意义(P<0.05)。结论 参麦注射液能进一步提高结直肠癌化疗的疗效,改善免疫功能及生存质量。
Abstract
Objective To investigate the effect of Shenmai injection combined with spleen polypeptide on immune function in patients with colorectal cancer undergoing chemotherapy.Methods Eighty-eight patients with colorectal cancer were divided into the study group and the control group. All these patients underwent XELOX chemotherapy. The control group was treated with spleen polypeptide while the study group was additionally treated with Shenmai injection. The efficacy of the two groups was evaluated according to the efficacy criteria of RECIST solid tumors. Serum CD3+, CD4+, CD4+/CD8+ and NK cells were detected in the two groups before and after treatment. The quality of life of patients in the two groups was assessed by KPS. The incidence of adverse reactions in the two groups was recorded.Results The difference in the remission rate was not statistically significant between the two groups (P>0.05). The effective rate of the study group was higher than that of the control group. The difference was statistically significant (P<0.05). The levels of CD3+, CD4+, CD4+/CD8+ and NK cells in the study group were significantly higher than those in the control group after treatment. The difference was statistically significant (P<0.05). The quality of life was improved more significantly in the study group than in the control group. The difference was statistically significant (P<0.05). The incidence of nausea and vomiting, leukocyte reduction, liver injury and neurotoxicity in the study group was lower than that in the control group. The difference was of statistical significance (P<0.05).Conclusion Shenmai injection can enhance the curative effect of colorectal cancer chemotherapy while improving the immune function and quality of life of patients.
关键词
参麦注射液 /
脾多肽 /
结直肠癌 /
免疫功能
Key words
Shenmai injection /
spleen polypeptide /
colorectal cancer /
immune function
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 郑 树, 张苏展, 黄彦钦. 结直肠癌研究30年回顾和现状[J]. 实用肿瘤杂志, 2016, 31(1):2-5.
[2] 陈爱霞, 杜杏坤, 吴春晓,等. 结直肠癌患者脾多肽联合FOLFOX4方案治疗效果观察[J]. 山东医药, 2018,6(9):245-246.
[3] 李 盼, 王 婷, 付姝菲,等. 基于Meta分析的参附、参麦注射液临床作用比较[J]. 中草药, 2016, 47(16):2949-2959.
[4] 傅维良. 实用肿瘤内科手册[M]. 沈阳:辽宁科学技术出版社, 1996:495-497.
[5] Eisenhauer E A, Verweij J, Eisenhauer E A, et al. 11 New response evaluation criteria in solid tumors: RECIST GUIDELINE VERSION 1.1[J]. EJC Supplements, 2009, 7(2):5.
[6] 林千鹤子. 抗癌药物毒副反应的对策[J]. 日本医学介绍, 2001, 22(11):491-493.
[7] 石会勇, 徐忠法. 结直肠癌化疗的研究进展[J]. 中华肿瘤防治杂志, 2012, 19(24):1915-1918.
[8] 金云刚, 周盛元, 陈 川. 脾多肽注射液对直肠癌患者免疫功能及炎症反应的影响[J]. 中国肿瘤临床与康复, 2017, 30(11):1360-1364.
[9] 杨 兵, 杨 柱, 唐东昕,等. 中医药在结直肠癌中的防治作用[J]. 现代中西医结合杂志, 2016, 25(21):2389-2392.
[10] 文 亢, 李 俊. 参麦注射液联合FOLFOX方案治疗结直肠癌的临床研究[J]. 陕西中医, 2015, 7(1):3-6.
[11] 高承贤, 丁志山, 尹丽慧,等. 参麦注射液对移植性肿瘤血管生成的影响[J]. 中成药, 2003, 25(9):728-731.
[12] 魏荣富, 金茂勇. 参麦注射液联合TP化疗方案对乳腺癌术后患者的疗效观察及生存质量的影响[J]. 实用癌症杂志, 2016, 31(7):1088-1090.
[13] 吴玖斌, 谢雁鸣, 王连心,等. 参麦注射液辅助治疗恶性肿瘤的有效性及安全性系统评价[J]. 中国中医基础医学杂志, 2014, 12(11):1525-1528.
[14] 张景淳, 郑桐森, 张艳桥. 免疫评分在结直肠癌中的研究进展[J]. 中国肿瘤, 2017, 26(8):612-616.
PDF(567 KB)
